CO2020004804A2 - Métodos de administración de una inmunoterapia con receptores de antígenos quiméricos - Google Patents

Métodos de administración de una inmunoterapia con receptores de antígenos quiméricos

Info

Publication number
CO2020004804A2
CO2020004804A2 CONC2020/0004804A CO2020004804A CO2020004804A2 CO 2020004804 A2 CO2020004804 A2 CO 2020004804A2 CO 2020004804 A CO2020004804 A CO 2020004804A CO 2020004804 A2 CO2020004804 A2 CO 2020004804A2
Authority
CO
Colombia
Prior art keywords
cell lymphoma
antigen receptor
chimeric antigen
methods
administration
Prior art date
Application number
CONC2020/0004804A
Other languages
English (en)
Inventor
Jeffrey S Wiezorek
Original Assignee
Kite Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kite Pharma Inc filed Critical Kite Pharma Inc
Publication of CO2020004804A2 publication Critical patent/CO2020004804A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)

Abstract

La descripción proporciona células que comprenden una inmunoterapia con linfocitos T autólogos modificados genéticamente del receptor de antígeno quimérico (CAR) dirigidos a CD19 para el tratamiento de, por ejemplo, linfoma de linfocitos B grandes recidivante o refractario luego de dos o más líneas de terapia sistémica, que incluyen linfoma difuso de linfocitos B grandes (DLBCL) no especificado de otra forma, linfoma primario mediastinal de linfocitos B grandes, linfoma de linfocitos B de grado alto y DLBCL que surge del linfoma folicular. Algunos aspectos de la descripción se relacionan con los métodos de tratamiento y monitoreo luego de la infusión de la terapia con linfocitos T proporcionados en la presente.
CONC2020/0004804A 2017-10-18 2020-04-17 Métodos de administración de una inmunoterapia con receptores de antígenos quiméricos CO2020004804A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762574159P 2017-10-18 2017-10-18
PCT/US2018/056467 WO2019079564A1 (en) 2017-10-18 2018-10-18 METHODS OF DELIVERY OF CHIMERIC ANTIGEN RECEPTOR IMMUNOTHERAPY

Publications (1)

Publication Number Publication Date
CO2020004804A2 true CO2020004804A2 (es) 2020-05-05

Family

ID=64477267

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0004804A CO2020004804A2 (es) 2017-10-18 2020-04-17 Métodos de administración de una inmunoterapia con receptores de antígenos quiméricos

Country Status (15)

Country Link
US (2) US20190151361A1 (es)
EP (1) EP3697500A1 (es)
JP (3) JP2021500333A (es)
KR (3) KR20230011487A (es)
CN (1) CN111479613A (es)
AR (1) AR113777A1 (es)
AU (4) AU2018351046A1 (es)
BR (1) BR112020007493A2 (es)
CA (1) CA3084470A1 (es)
CO (1) CO2020004804A2 (es)
IL (2) IL273629B2 (es)
MX (2) MX421741B (es)
SG (1) SG11202003380TA (es)
TW (2) TWI866888B (es)
WO (1) WO2019079564A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3567049A4 (en) 2016-12-28 2020-08-26 Green Cross Lab Cell Corporation CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME
KR102774451B1 (ko) 2017-11-14 2025-02-28 앱클론(주) 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
JP7174777B2 (ja) 2018-06-01 2022-11-17 カイト ファーマ インコーポレイテッド キメラ抗原受容体ｔ細胞療法
US20210346601A1 (en) * 2018-09-24 2021-11-11 Amgen Inc. Interventional dosing systems and methods
AU2019397033B2 (en) 2018-12-12 2023-06-29 Kite Pharma, Inc. Chimeric antigen receptors and CAR-T cells and methods of use
MX2021013359A (es) * 2019-04-30 2022-01-31 Crispr Therapeutics Ag Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19.
CN118593691A (zh) * 2019-05-03 2024-09-06 凯德药业股份有限公司 施用嵌合抗原受体免疫疗法的方法
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
CN114845729A (zh) * 2019-11-13 2022-08-02 克里斯珀医疗股份公司 使用靶向cd70的基因工程化t细胞的cd70+实体瘤疗法
CN116685337A (zh) * 2020-10-20 2023-09-01 克里斯珀医疗股份公司 使用靶向cd19的基因工程化t细胞的b细胞恶性肿瘤的同种异体细胞疗法
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
US20240148790A1 (en) * 2022-10-28 2024-05-09 Kite Pharma, Inc. Expedited administration of engineered lymphocytes
TW202530421A (zh) 2022-10-28 2025-08-01 美商凱特製藥公司 用於將免疫療法最佳化之因素
KR20240119436A (ko) 2023-01-30 2024-08-06 에이치엘만도 주식회사 스티어링 휠의 핸즈 온/오프 감지 장치 및 방법
KR20250162836A (ko) 2023-03-17 2025-11-19 카이트 파마 인코포레이티드 종양 미세환경이 면역요법의 효능에 미치는 영향
US20250161361A1 (en) 2023-11-01 2025-05-22 Kite Pharma, Inc. Factors for optimizing immunotherapy efficacy
US20250290154A1 (en) 2024-03-04 2025-09-18 Kite Pharma, Inc. Predictive markers for immunotherapy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
KR20140004174A (ko) 2011-01-18 2014-01-10 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 치료를 위한 조성물 및 방법
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
CN103946952A (zh) 2011-09-16 2014-07-23 宾夕法尼亚大学董事会 用于治疗癌症的rna改造的t细胞
HRP20230297T1 (hr) * 2012-07-13 2023-05-12 The Trustees Of The University Of Pennsylvania UPRAVLJANJE TOKSIČNOŠĆU ZA ANTI-TUMORSKO DJELOVANJE CAR-a
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
AU2015214145A1 (en) * 2014-02-04 2016-08-25 Kite Pharma. Inc. Methods for producing autologous T cells useful to treat B cell malignancies and other cancers and compositions thereof
CN106701827A (zh) * 2016-12-05 2017-05-24 刘晓明 表达cd19和cd20抗体基因嵌合抗原受体t细胞的转化及扩增培养与保存方法

Also Published As

Publication number Publication date
TW202510896A (zh) 2025-03-16
IL273629B2 (en) 2025-10-01
EP3697500A1 (en) 2020-08-26
JP2021500333A (ja) 2021-01-07
AR113777A1 (es) 2020-06-10
CN111479613A (zh) 2020-07-31
JP2023154073A (ja) 2023-10-18
IL320802A (en) 2025-07-01
KR20250054837A (ko) 2025-04-23
US20190151361A1 (en) 2019-05-23
KR20230011487A (ko) 2023-01-20
IL273629B1 (en) 2025-06-01
MX2020004094A (es) 2020-07-21
AU2021282551A1 (en) 2022-01-06
KR20200071753A (ko) 2020-06-19
AU2021282551B2 (en) 2023-01-19
CA3084470A1 (en) 2019-04-25
AU2025220739A1 (en) 2025-09-11
AU2018351046A1 (en) 2020-04-30
NZ763357A (en) 2023-10-27
MX2025002021A (es) 2025-04-02
AU2023202308B2 (en) 2025-05-22
TW201927315A (zh) 2019-07-16
AU2023202308A1 (en) 2023-05-11
WO2019079564A1 (en) 2019-04-25
SG11202003380TA (en) 2020-05-28
MX421741B (es) 2025-03-14
JP2026048753A (ja) 2026-03-17
US20240058381A1 (en) 2024-02-22
IL273629A (en) 2020-05-31
TWI866888B (zh) 2024-12-21
BR112020007493A2 (pt) 2020-10-27

Similar Documents

Publication Publication Date Title
CO2020004804A2 (es) Métodos de administración de una inmunoterapia con receptores de antígenos quiméricos
MX2021013394A (es) Métodos para administrar inmunoterapia con receptor de antígeno quimérico.
MX2019014008A (es) Composiciones y usos para inmunoterapia.
MX2017015046A (es) Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos.
MX2016010856A (es) Metodo.
SA517381666B1 (ar) B مستقبلات مولد ضد خيمري تستهدف مولد ضد نضج الخلايا
CO2019000946A2 (es) Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos
CO2018004315A2 (es) Conjugados de 2-amino-pirrolo [3,2] pirimidina con anticuerpos anti-her-2
MX2017007575A (es) Receptores de antígenos quiméricos de antígeno de maduración de células b.
MX2025002686A (es) Anticuerpo anti-cd20 de tipo ii y usos del mismo
DOP2018000212A (es) Moléculas de unión a bcma y métodos de uso de las mismas
CL2018002828A1 (es) Anticuerpos biespecíficos contra el receptor de fc gamma cd25 para la reducción de células específicas de tumores.
MX2017006408A (es) Linfocitos t gamma delta modificados geneticamente.
MX2018008106A (es) Terapias con celulas inmunoefectoras de una eficacia mejorada.
HK1258041A1 (zh) 免疫细胞组合物和使用方法
AR110676A1 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
CO2017001573A2 (es) Receptor quimérico de antígeno anti-cd123
MX2017007138A (es) Metodos y composiciones para terapia celular adoptiva.
MX393750B (es) Inmunoterapia antitumoral combinada.
MX2017006865A (es) Receptores de células t de kras anti-mutado.
MX2017014193A (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
PH12016501976A1 (en) Antibodies, pharmaceutical compositions and uses thereof
GT201600171A (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblástica aguda
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
EP4406610A3 (en) Treatment of cancer using anti-cd19 chimeric antigen receptor